Methoxy polyethylene glycol-epoetin beta
- Generic Name
- Methoxy polyethylene glycol-epoetin beta
- Brand Names
- Mircera
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 677324-53-7
- Unique Ingredient Identifier
- LR3UXN0193
- Background
Methoxy polyethylene glycol-epoetin beta is a chemically synthesised Erythropoiesis Stimulating Agent (ESA) with a longer half-life than erythropoietin. ESA is used to increase synthesis of red blood cells to treat chronic kidney disease associated anemia.
- Indication
For the treatment of patients with anaemia associated with chronic kidney disease. Not a substitute for RBC transfusion if immediate correction of anemia is required.
- Associated Conditions
- Anemia
- Associated Therapies
- -
An Observational Study to Evaluate the Effectiveness of Mircera Treatment for Renal Anemia in Pre-dialysis Participants With Chronic Kideny Disease (CKD)
- Conditions
- Kidney Disease, Chronic
- Interventions
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 393
- Registration Number
- NCT02547454
- Locations
- 🇸🇮
Hospital Celje; Dept For Kidney Disease & Dialysis, Celje, Slovenia
🇸🇮Splosna Bolnisnica Izola; Oddelek Za Nefrologijo, Izola, Slovenia
🇸🇮Clinical Centre Ljubljana; Clinical Dep. For Nephrology, Ljubljana, Slovenia
An Observational Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) in Chronic Kidney Disease Participants on Dialysis
- Conditions
- Chronic Kidney Diseases
- Interventions
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 197
- Registration Number
- NCT02238080
- Locations
- 🇮🇱
Holy Family Hospital; Nephrology, Nazareth, Israel
🇮🇱Rebecca Sief Hospital; Nephrology, Safed, Israel
🇮🇱Sourasky MC; Dept. of Nephrology, Tel Aviv, Israel
Frequent Dosing of CERA Improves Nutrition and Inflammation in Hemodialysis Patients
- First Posted Date
- 2014-09-05
- Last Posted Date
- 2014-09-05
- Lead Sponsor
- Taipei Veterans General Hospital, Taiwan
- Target Recruit Count
- 67
- Registration Number
- NCT02232113
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
Comparison Among Erythropoietin Stimulating Agents
- Conditions
- Anemia of End Stage Renal Disease
- Interventions
- Drug: Epoetin alpha or beta (Epoetin group)Drug: Darbepoetin alfaDrug: Methoxy polyethylene glycol-epoetin beta
- First Posted Date
- 2014-01-30
- Last Posted Date
- 2017-09-13
- Lead Sponsor
- Hamad Medical Corporation
- Target Recruit Count
- 327
- Registration Number
- NCT02049346
- Locations
- 🇶🇦
Fahd Bin Jassem Dialysis Centre, Doha, Qatar
A Study to Assess Hemoglobin Level Depending on the Comorbidity Index in Chronic Kidney Disease (CKD) Participants Not in Dialysis Treated With Methoxy Polyethylene Glycol-Epoetin Beta (COMETE)
- Conditions
- Renal Anemia of Chronic Kidney Disease
- Interventions
- First Posted Date
- 2012-12-27
- Last Posted Date
- 2019-07-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 551
- Registration Number
- NCT01756612
- Locations
- 🇫🇷
Hopital Claude Huriez; Nephrologie, Lille, France
🇫🇷Ctre Hosp St Joseph Et St Luc; Nephrologie Hemodialyse, Lyon, France
🇫🇷Polyclinique De La Louviere; Nephrologie, Lille, France
A Study of The Effect of Altitude on Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) Dose Requirements in Participants With Chronic Renal Anemia in Pre-Dialysis or Dialysis
- Conditions
- Anemia, Kidney Disease, Chronic
- Interventions
- First Posted Date
- 2012-01-27
- Last Posted Date
- 2019-06-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 87
- Registration Number
- NCT01519947
- Locations
- 🇲🇽
Unidad De Dialisis La Loma S.C., Pureto Vallarta, Mexico
🇲🇽Clínica San Cosme Centro Especializado en el Tratamiento de Enfermedades Renales S.C, Aguascalientes, Mexico
🇲🇽Nefros Investigación S.C., Delegación Coyoacan, Mexico
A Study of Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in Participants With Chronic Kidney Disease (PRIMAVERA)
- Conditions
- Kidney Disease, Chronic
- Interventions
- Drug: PlaceboDrug: Methoxy polyethylene glycol-epoetin beta
- First Posted Date
- 2010-09-02
- Last Posted Date
- 2017-05-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 241
- Registration Number
- NCT01194154
- Locations
- 🇩🇪
Klinikum d.Universität München Campus Großhadern, München, Germany
🇩🇪Nierenzentrum Bogenhausen/Perlach; Praxis für Nierenheilkunde, München-Bogenhausen, Germany
🇩🇪Charité - Klinikum Mitte; Medizinische Klinik Für Nephrologie, Berlin, Germany
A Study of Monthly Subcutaneous Continuous Erythropoietin Receptor Activator (CERA) in Predialysis Participants With Chronic Renal Anemia
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2016-04-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 140
- Registration Number
- NCT00773968
A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)
- Conditions
- Chronic Renal Anemia
- Interventions
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2825
- Registration Number
- NCT00773513
- Locations
- 🇦🇺
Gosford Hospital; Renal, Gosford, New South Wales, Australia
🇭🇷General Hospital Josip Bencevic; Department of Haemodialysis, Slavonski Brod, Croatia
🇦🇺Renal Research Dr Simon Roger, Gosford, New South Wales, Australia
A Study of Monthly Subcutaneous (SC) Mircera for Maintenance Treatment of Participants With Chronic Kidney Disease on Peritoneal Dialysis
- First Posted Date
- 2008-08-19
- Last Posted Date
- 2017-06-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 96
- Registration Number
- NCT00737477
- Locations
- 🇫🇷
Arauco; Arauco Tours Bretonneau, Tours, France
🇫🇷Centre Hospitalier; Hemodialyse, Annonay, France
🇫🇷Ch Notre Dame Misericorde; Hemodialyse, Ajaccio, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.